The FDA-approved lung cancer drug osimertinib (sold under the brand name Tagrisso) slashes the risk of death by 51% for certain patients whose cancer is caught early, according to new trial data. “This should be the new standard of care for these patients,” Nathan Pennell, co-director of the Cleveland Clinic Lung Cancer Program, who wasn’t involved in the drug’s development, said in a statement for the American Society of Clinical Oncology. The drug: Lung cancer is the second-most common cancer in the world, with 2.2 million new diagnoses every year. The vast majority fall into a category called “non-small cell...